Form 4: Regeneron EVP Andrew Murphy Executes Stock Option and Sells Shares Under 10b5-1 Plan

Regeneron's EVP of Research, Andrew Murphy, exercised stock options and sold shares of common stock on August 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Murphy, EVP of Research at Regeneron Pharmaceuticals, exercised a non-qualified stock option to acquire 20,000 shares of common stock on August 13, 2024, at a price of $399.66 per share.
• Concurrently, Murphy disposed of 20,000 shares acquired from the option exercise.
• On August 13, 2024, Murphy disposed of 13,637 shares to cover tax obligations at a price of $1,141.49.
• On August 14, 2024, Murphy sold a total of 5,342 shares of common stock in multiple transactions at prices ranging from $1,140.31 to $1,159.69 per share.
• These transactions were executed under a pre-arranged trading plan pursuant to Rule 10b5-1(c), adopted on May 9, 2023.
• Following these transactions, Murphy directly owns 48,306 shares of Regeneron common stock and indirectly owns 4,326 shares through a 401(k) plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine executive stock transactions under a pre-arranged plan, which is a common practice.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are usually not a cause for concern.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Trading plans under Rule 10b5-1 are a standard practice for corporate insiders to sell shares without raising concerns about insider trading.
• Comparable companies like Amgen, Gilead, and Biogen also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on shareholders, as they are part of a pre-planned trading strategy.

Key Dates